ARTICLE | Company News
GlaxoSmithKline licenses sepsis compound
February 22, 2001 8:00 AM UTC
Sepsicure granted GlaxoSmithKline (GSK; LSE:GSK) development and marketing rights to GR 270773, a lipid emulsion that binds endotoxin. The product is about to enter Phase II testing to treat sepsis. S...